Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $102.00

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its target price hoisted by Wedbush from $99.00 to $102.00 in a report released on Wednesday morning,Benzinga reports. They currently have an outperform rating on the stock.

Several other research analysts have also issued reports on the company. Canaccord Genuity Group raised their target price on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Citigroup upped their target price on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Zacks Research downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 30th. Wells Fargo & Company raised their price target on shares of Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, Weiss Ratings upgraded shares of Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, October 8th. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, Kiniksa Pharmaceuticals International has a consensus rating of “Moderate Buy” and a consensus target price of $100.57.

Kiniksa Pharmaceuticals International Stock Down 5.5%

NASDAQ KNSA opened at $92.24 on Wednesday. The firm has a 50-day moving average price of $79.15 and a two-hundred day moving average price of $60.03. The company has a market capitalization of $7.20 billion, a P/E ratio of 70.95 and a beta of 0.04. Kiniksa Pharmaceuticals International has a 12-month low of $36.56 and a 12-month high of $98.48.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. The firm had revenue of $285.97 million for the quarter, compared to the consensus estimate of $260.66 million. Equities analysts expect that Kiniksa Pharmaceuticals International will post 1.26 EPS for the current year.

Insider Activity

In other news, CAO Michael Megna sold 4,600 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $80.30, for a total transaction of $369,380.00. Following the completion of the sale, the chief accounting officer owned 29,062 shares of the company’s stock, valued at $2,333,678.60. This trade represents a 13.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 51.98% of the company’s stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of large investors have recently bought and sold shares of KNSA. Curry Webb Wealth Management LLC bought a new position in Kiniksa Pharmaceuticals International during the third quarter valued at about $29,000. Allworth Financial LP lifted its holdings in Kiniksa Pharmaceuticals International by 42.0% during the second quarter. Allworth Financial LP now owns 453 shares of the company’s stock valued at $29,000 after purchasing an additional 134 shares during the last quarter. Nykredit A S purchased a new stake in Kiniksa Pharmaceuticals International during the second quarter valued at about $34,000. KBC Group NV purchased a new stake in Kiniksa Pharmaceuticals International during the first quarter valued at about $34,000. Finally, USA Financial Formulas purchased a new stake in Kiniksa Pharmaceuticals International during the third quarter valued at about $69,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.